These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26342407)

  • 41. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer.
    Qureshi KN; Griffiths TR; Robinson MC; Marsh C; Roberts JT; Hall RR; Lunec J; Neal DE
    Clin Cancer Res; 1999 Nov; 5(11):3500-7. PubMed ID: 10589764
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
    Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Claudin-11 decreases the invasiveness of bladder cancer cells.
    Awsare NS; Martin TA; Haynes MD; Matthews PN; Jiang WG
    Oncol Rep; 2011 Jun; 25(6):1503-9. PubMed ID: 21468549
    [TBL] [Abstract][Full Text] [Related]  

  • 44. EGFR antibody-supplemented TPE-chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.
    Knecht R; Peters S; Solbach C; Baghi M; Gstöttner W; Hambek M
    Anticancer Res; 2003; 23(6C):4789-95. PubMed ID: 14981927
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiangiogenesis targeting tumor microenvironment synergizes glucuronide prodrug antitumor activity.
    Juan TY; Roffler SR; Hou HS; Huang SM; Chen KC; Leu YL; Prijovich ZM; Yu CP; Wu CC; Sun GH; Cha TL
    Clin Cancer Res; 2009 Jul; 15(14):4600-11. PubMed ID: 19584154
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization and evaluation of the antitumour activity of a dual-targeting monoclonal antibody against claudin-3 and claudin-4.
    Kato-Nakano M; Suzuki M; Kawamoto S; Furuya A; Ohta S; Nakamura K; Ando H
    Anticancer Res; 2010 Nov; 30(11):4555-62. PubMed ID: 21115905
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
    Tonra JR; Deevi DS; Corcoran E; Li H; Wang S; Carrick FE; Hicklin DJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2197-207. PubMed ID: 16609035
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
    Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
    Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel anti-EPHA2 antibody, DS-8895a for cancer treatment.
    Hasegawa J; Sue M; Yamato M; Ichikawa J; Ishida S; Shibutani T; Kitamura M; Wada T; Agatsuma T
    Cancer Biol Ther; 2016 Nov; 17(11):1158-1167. PubMed ID: 27653549
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of Nuclear Claudin-4 in Renal Cell Carcinoma.
    Owari T; Sasaki T; Fujii K; Fujiwara-Tani R; Kishi S; Mori S; Mori T; Goto K; Kawahara I; Nakai Y; Miyake M; Luo Y; Tanaka N; Kondoh M; Fujimoto K; Kuniyasu H
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33172177
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.
    Suzuki M; Kato-Nakano M; Kawamoto S; Furuya A; Abe Y; Misaka H; Kimoto N; Nakamura K; Ohta S; Ando H
    Cancer Sci; 2009 Sep; 100(9):1623-30. PubMed ID: 19555390
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Generation and characterization of a human-mouse chimeric antibody against the extracellular domain of claudin-1 for cancer therapy using a mouse model.
    Hashimoto Y; Tada M; Iida M; Nagase S; Hata T; Watari A; Okada Y; Doi T; Fukasawa M; Yagi K; Kondoh M
    Biochem Biophys Res Commun; 2016 Aug; 477(1):91-95. PubMed ID: 27286708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin.
    Miao L; Wang Y; Lin CM; Xiong Y; Chen N; Zhang L; Kim WY; Huang L
    J Control Release; 2015 Nov; 217():27-41. PubMed ID: 26285063
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety evaluation of a human chimeric monoclonal antibody that recognizes the extracellular loop domain of claudin-2.
    Hashimoto Y; Hata T; Tada M; Iida M; Watari A; Okada Y; Doi T; Kuniyasu H; Yagi K; Kondoh M
    Eur J Pharm Sci; 2018 May; 117():161-167. PubMed ID: 29448044
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hypomethylation of
    Maesaka F; Kuwada M; Horii S; Kishi S; Fujiwara-Tani R; Mori S; Fujii K; Mori T; Ohmori H; Owari T; Miyake M; Nakai Y; Tanaka N; Bhawal UK; Luo Y; Kondoh M; Fujimoto K; Kuniyasu H
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742959
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Generation of specific monoclonal antibodies against the extracellular loops of human claudin-3 by immunizing mice with target-expressing cells.
    Ando H; Suzuki M; Kato-Nakano M; Kawamoto S; Misaka H; Kimoto N; Furuya A; Nakamura K
    Biosci Biotechnol Biochem; 2015; 79(8):1272-9. PubMed ID: 25744656
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies.
    Kita Y; Hamada A; Saito R; Teramoto Y; Tanaka R; Takano K; Nakayama K; Murakami K; Matsumoto K; Akamatsu S; Yamasaki T; Inoue T; Tabata Y; Okuno Y; Ogawa O; Kobayashi T
    Br J Cancer; 2019 Dec; 121(12):1027-1038. PubMed ID: 31673101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.